Department of Biology, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Department of Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357-15794, Iran.
Curr Stem Cell Res Ther. 2020;15(4):340-348. doi: 10.2174/1574888X15666200316164051.
Spinal Cord Injury (SCI), as a devastating and life-altering neurological disorder, is one of the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and surgical decompression. Both the approaches have been observed to have adverse physiological effects on SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required for developing cell-based therapies. Multipotent stem cells, as a novel strategy for the treatment of tissue injury, may provide an effective therapeutic option against many neurological disorders. Mesenchymal stem cells (MSCs) or multipotent stromal cells can typically self-renew and generate various cell types. These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs), umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have remarkable potential for the development of regenerative therapies in animal models and humans with SCI. Herein, we summarize the therapeutic potential of human MSCs in the treatment of SCI.
脊髓损伤(SCI)是一种严重的、改变生活的神经疾病,是最严重的健康问题之一。目前,急性 SCI 的治疗包括药物治疗和手术减压。这两种方法都被观察到对 SCI 患者有不良的生理影响。因此,迫切需要针对 SCI 管理的新治疗靶点来开发基于细胞的治疗方法。多能干细胞作为治疗组织损伤的一种新策略,可能为许多神经疾病提供有效的治疗选择。间充质干细胞(MSCs)或多能基质细胞可以自我更新并产生各种细胞类型。这些细胞通常从骨髓(BM-MSCs)、脂肪组织(AD-MSCs)、脐带血(UCB-MSCs)和胎盘(PMSCs)中分离出来。MSCs 在动物模型和 SCI 人类患者的再生治疗开发中具有显著的潜力。本文总结了人 MSCs 在治疗 SCI 中的治疗潜力。